Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 54 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy	Fulvestrant (Faslodex) , Taselisib (GDC-0032; RG-7604)	Breast cancer	Breast Cancer	2017	View \| Download
Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2019	View \| Download
Trastuzumab deruxtecan for metastatic HER2 - positive breast cancer – second line	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2020	View \| Download
Trastuzumab deruxtecan for treating HER2-low, HR-positive, metastatic breast cancer	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2022	View \| Download
Trastuzumab deruxtecan for unresectable or metastatic HER2-low (HR+/-) breast cancer – after chemotherapy	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2021	View \| Download
Trastuzumab deruxtecan neoadjuvant therapy for high-risk HER2-positive early stage breast cancer	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2023	View \| Download
Trastuzumab duocarmazine for third-line treatment of HER2-positive unresectable metastatic breast cancer	Trastuzumab duocarmazine	Breast cancer	Breast Cancer	2023	View \| Download
Trastuzumab Emtansine for HER2-positive breast cancer - adjuvant	Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365)	Breast cancer	Breast Cancer	2018	View \| Download
Trastuzumab emtansine in combination with pertuzumab for HER2-positive early breast cancer - adjuvant therapy	Pertuzumab (Perjeta; R-1273) , Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365)	Breast cancer	Breast Cancer	2019	View \| Download
Tucatinib in addition to trastuzumab and capecitabine for advanced breast cancer	Capecitabine (Xeloda) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380)	Breast cancer	Breast Cancer	2020	View \| Download